Our Services
At Basanti BioMedical, our research and development work is anchored in three core areas of oncology science. Each focus area is designed to address unmet needs in cancer treatment through novel molecular strategies, proprietary platform development, and cutting-edge therapeutic design.
- Home
- Services
Novel Anticancer Molecule Design and Development
We design and develop first-in-class anticancer molecules targeting key oncogenic pathways, with demonstrated preclinical evidence of efficacy in varied types of cancers systems including Hepatocellular Carcinoma, Colon Carcinoma, and Triple Negative Breast Cancer (TNBC).
What This Involves
Our molecule development process begins with identifying disease-causing proteins in target cancer systems and engineering molecules with the precision to selectively engage and eliminate them. The proprietary therapeutic molecule developed at Basanti BioMedical is designed to overcome the key limitations of conventional oncology drugs — poor on-target delivery, insufficient on-target efficacy, and harmful off-target toxicity.
Why this matters
- Targets cancers with limited treatment success under conventional approaches
- Designed for selectivity — minimal harm to healthy tissue
- Preclinical studies actively underway with early evidence of efficacy
- Patent application in progress for the proprietary therapeutic molecule
Indigenous Linker Platform Development
We are developing a proprietary, India-originated linker platform that forms the backbone of our multifunctional therapeutic architecture. This linker platform enables precise intracellular targeting and is a critical differentiator of our approach to targeted protein degradation.
What This Involves
The linker in a targeted protein degrader is not a passive connector — it determines how effectively the degrader recruits the cell’s own machinery to destroy disease-causing proteins. Our novel linker design addresses the structural and functional challenges that limit existing degrader technologies, enabling improved selectivity, stability, and degradation efficiency.
Why this matters
- Proprietary and independently developed in India
- Central to the mechanism of action of our therapeutic molecule
- Overcomes key structural limitations of existing linker technologies
- Patent application in progress for the novel linker platform
PROTAC Design and Development
We are engaged in the design and development of Proteolysis Targeting Chimeras (PROTACs) — a next-generation class of therapeutic molecules that harness the cell’s own ubiquitin-proteasome system to selectively degrade disease-causing proteins.
What This Involves
Unlike traditional inhibitors that simply block a protein’s function, PROTACs physically eliminate the target protein from within the cell. This catalytic mechanism of action offers significant advantages — including the ability to overcome drug resistance, address previously “undruggable” targets, and achieve sustained therapeutic effect at lower doses. Our PROTAC development efforts are integrated with our proprietary linker platform and anticancer molecule program, creating a cohesive and differentiated oncology pipeline.
Why this matters
- Addresses “undruggable” cancer targets inaccessible to conventional drugs
- Catalytic action allows sustained effect — the PROTAC is not consumed in the reaction
- Potential to overcome acquired drug resistance in cancer cells
- Builds directly on our proprietary linker and molecule development programs
Frequently Asked Questions
We are currently focused on p53-relevant cancer systems, specifically Hepatocellular Carcinoma (liver cancer), Colon Carcinoma (colorectal cancer), and Triple Negative Breast Cancer (TNBC) — cancers where conventional treatment options have significant limitations.
A targeted protein degrader is a therapeutic molecule designed to selectively identify and destroy disease-causing proteins inside a cancer cell, using the cell's own natural protein disposal system (the ubiquitin-proteasome system). Unlike traditional drugs that only block a protein's activity, degraders physically eliminate the protein, offering a more complete and durable therapeutic effect.
Basanti BioMedical is currently at the In vitro target validation stage and on the verge of Preclinical stage.
Our proprietary linker platform based targeted protein degrader has shown potential killing effects in target cancer cell systems. In-vitro experiment and target validation underway, we are in-process for filing a series of patent applications on our novel linker platform as well as our proprietary therapeutic molecule.
Our receptor-directed hetero-bifunctional targeted protein degrader selectively binds to cancer cells and kills them through lysis of disease-causing proteins. This directly overcomes the three core limitations of conventional targeted therapies: inadequate on-target delivery, insufficient on-target efficacy, and harmful off-target toxicity — making it a potentially transformative approach in the oncology field.